Subscribe
nobeastsofierce
nobeastsofierce / Shutterstock.com
6 August 2020BiotechnologyRory O'Neill

LSPN Connect: micro-managing with Pendulum Therapeutics

With any rapidly-developing field, particularly the life sciences, the importance of a coherent IP strategy cannot be ignored.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Big Pharma
LSPN Connect: MPP chief wants COVID-19 role
26 June 2020   The executive director of the Medicines Patent Pool says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Big Pharma
LSPN Connect: MPP chief wants COVID-19 role
26 June 2020   The executive director of the Medicines Patent Pool says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.

More on this story

Americas
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Big Pharma
LSPN Connect: MPP chief wants COVID-19 role
26 June 2020   The executive director of the Medicines Patent Pool says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.

More features

McGuireWoods expands team with ex-Novo Nordisk GC
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Bristol Myers Squibb leader named INTA 2025 president
Kathi Vidal to leave USPTO ahead of incoming Trump administration